{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:09:11Z","timestamp":1793250551478,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005895","name":"Fred Hutchinson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.blre.2025.101286","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T09:06:06Z","timestamp":1742634366000},"page":"101286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Haploidentical transplantation: An optimal platform for graft manipulation and cellular therapies"],"prefix":"10.1016","volume":"72","author":[{"given":"C.C.","family":"Astigarraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klauberg","family":"MPMS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.blre.2025.101286_bb0005","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2025.101286_bb0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/sci-2021-058","article-title":"Racial disparities in hematopoietic stem cell transplant: a systematic review of the literature","volume":"8","author":"Landry","year":"2021","journal-title":"Stem Cell Investig"},{"issue":"6","key":"10.1016\/j.blre.2025.101286_bb0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOH.0000000000000835","article-title":"Unrelated hematopoietic stem cell donor registries: present reality and future prospects","volume":"31","author":"Schmidt","year":"2024","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101286_bb0020","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2366718","article-title":"Future directions in haploidentical hematopoietic stem cell transplantation","volume":"29","author":"Vittayawacharin","year":"2024","journal-title":"Hematology"},{"issue":"6","key":"10.1016\/j.blre.2025.101286_bb0025","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bbmt.2010.08.023","article-title":"Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison","volume":"17","author":"Wang","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.blre.2025.101286_bb0030","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.2019001323","article-title":"How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide","volume":"134","author":"McCurdy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101286_bb0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-019-0751-4","article-title":"Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT","volume":"12","author":"Piemontese","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101286_bb0040","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2006.07.0953","article-title":"Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution","volume":"25","author":"Rizzieri","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2025.101286_bb0045","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1182\/bloodadvances.2021006262","article-title":"Haploidentical donor-derived memory CAR T cells: first in human experience and in vitro correlative study","volume":"6","author":"Ukrainskaya","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101286_bb0050","article-title":"The development of post-transplant cyclophosphamide: half a century of translational team science","volume":"62","author":"O\u2019Donnell","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101286_bb0055","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3389\/fimmu.2019.02769","article-title":"The evolution of T cell depleted haploidentical transplantation","volume":"10","author":"Aversa","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101286_bb0065","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fimmu.2020.00191","article-title":"Key aspects of the immunobiology of haploidentical hematopoietic cell transplantation","volume":"11","author":"Bertaina","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101286_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.971709","article-title":"Gamma delta T-cell reconstitution after allogeneic HCT: a platform for cell therapy","volume":"13","author":"Gaballa","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.blre.2025.101286_bb0235","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","article-title":"Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited","volume":"36","author":"Deol","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.blre.2025.101286_bb0115","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood.V75.10.1947.1947","article-title":"Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells","volume":"75","author":"Kastan","year":"1990","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101286_bb0260","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41409-022-01839-8","article-title":"Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: a study on behalf of the EBMT cellular therapy & immunobiology working party","volume":"58","author":"Santoro","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2025.101286_bb0155","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s10875-021-01113-4","article-title":"Haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide for children with non-malignant diseases","volume":"41","author":"Hashem","year":"2021","journal-title":"J Clin Immunol"},{"issue":"11","key":"10.1016\/j.blre.2025.101286_bb0290","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30659","article-title":"Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post-transplant cyclophosphamide for treatment of high-risk myeloid neoplasms in children: a retrospective study","volume":"70","author":"Qi","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.blre.2025.101286_bb0285","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-018-3482-7","article-title":"Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBHCT for very high-risk hematologic malignancies","volume":"98","author":"Gao","year":"2018","journal-title":"Ann Hematol"},{"issue":"13","key":"10.1016\/j.blre.2025.101286_bb0345","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1182\/blood-2015-01-622662","article-title":"Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects","volume":"126","author":"Gartlan","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2025.101286_bb0355","first-page":"900","article-title":"T-cell tracking, safety, and effect of low-dose donor memory T-cell infusions after \u03b1\u03b2 T cell-depleted hematopoietic stem cell transplantation","volume":"56","author":"Shelikhova","year":"2021","journal-title":"Bone Marrow Transplant 2020"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101286_bb0360","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2023-187058","article-title":"Phase I trial of allogeneic donor gamma delta T cell infusion post-hematopoietic cell transplantation: an interim safety report","volume":"142","author":"Bejanyan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101286_bb0365","doi-asserted-by":"crossref","first-page":"S537","DOI":"10.1016\/S2152-2650(23)01528-8","article-title":"CT-632 ORCA-Q demonstrates favorable graft-versus-host disease (GvHD) and relapse-free survival with haploidentical donors without post-transplant cyclophosphamide","volume":"23","author":"Srour","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101286_bb0370","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1182\/blood-2023-179215","article-title":"SMART101 donor T-lymphoid progenitors to accelerate immune reconstitution post-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide: SI101-02 first-in-human phase I\/II","volume":"142","author":"Devillier","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101286_bb0375","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/hum.2010.014","article-title":"Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Lupo-Stanghellini","year":"2010","journal-title":"Hum Gene Ther"},{"issue":"5319","key":"10.1016\/j.blre.2025.101286_bb0380","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.blre.2025.101286_bb0385","first-page":"3681","article-title":"Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir","volume":"90","author":"Munshi","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101286_bb0390","first-page":"1448a","article-title":"Phase I\/II study of thymidine kinase (TK)-transduced donor lymphocyte infusions (DLI) in patients with hematologic malignancies","volume":"94","author":"Champlin","year":"1999","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2025.101286_bb0060","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","article-title":"Full haplotype mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse","volume":"23","author":"Aversa","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2025.101286_bb0070","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1182\/bloodadvances.2020003739","article-title":"Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia","volume":"5","author":"Pierini","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2025.101286_bb0075","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1242\/dmm.006668","article-title":"Mouse models of graft-versus-host disease: advances and limitations","volume":"4","author":"Schroeder","year":"2011","journal-title":"Dis Model Mech"},{"issue":"10","key":"10.1016\/j.blre.2025.101286_bb0080","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2017-08-752162","article-title":"The potential role of \u03b3\u03b4 T cells after allogeneic HCT for leukemia","volume":"131","author":"Handgretinger","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101286_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-021-01551-z","article-title":"Results of a multicenter phase I\/II trial of TCR\u03b1\u03b2 and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients","author":"Bethge","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2025.101286_bb0095","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.2023021336","article-title":"TCR\u03b1\u03b2\/CD19 cell\u2013depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis","volume":"143","author":"Merli","year":"2024","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2025.101286_bb0100","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood.2022015959","article-title":"KIR-favorable TCR-\u03b1\u03b2\/CD19-depleted haploidentical HCT in children with ALL\/AML\/MDS: primary analysis of the PTCTC ONC1401 trial","volume":"140","author":"Pulsipher","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101286_bb0105","doi-asserted-by":"crossref","DOI":"10.3892\/or.16.1.141","article-title":"Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide","author":"Motoyoshi","year":"2006","journal-title":"Oncol Rep"},{"issue":"211","key":"10.1016\/j.blre.2025.101286_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.blre.2025.101286_bb0120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2025.101286_bb0125","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.blre.2025.101286_bb0130","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.3390\/cancers15215246","article-title":"PTCY-based haploidentical donor transplantation versus HLA-matched related and unrelated donor transplantations in patients with refractory or relapsed lymphoma\u2014a matched-pair analysis","volume":"15","author":"Haebe","year":"2023","journal-title":"Cancers"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101286_bb0135","first-page":"780","article-title":"Post-transplant cyclophosphamide eliminates disparity in GvHD-free, relapse-free survival and overall survival between 8\/8 matched and 7\/8 mismatched unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies","volume":"142","author":"Auletta","year":"2023","journal-title":"ASH Annual Meeting"},{"issue":"25","key":"10.1016\/j.blre.2025.101286_bb0140","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101286_bb0145","author":"El Jurdi","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.blre.2025.101286_bb0150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00184","article-title":"Post-transplant cyclophosphamide\u2013based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","author":"Shaffer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2025.101286_bb0160","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.bbmt.2020.03.018","article-title":"HLA-haploidentical hematopoietic cell transplantation for treatment of nonmalignant diseases using nonmyeloablative conditioning and post-transplant cyclophosphamide","volume":"26","author":"Mallhi","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2025.101286_bb0165","first-page":"1712","article-title":"Salvage HLA-haploidentical hematopoietic stem cell transplantation for patients with non-malignant diseases and graft failure after previous allogeneic HHCT","volume":"56","author":"Giebel","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.blre.2025.101286_bb0170","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.3390\/ijms25126380","article-title":"Haploidentical HHCT in the treatment of pediatric hematological disorders","volume":"25","author":"Kowalewska","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.blre.2025.101286_bb0175","first-page":"407","article-title":"Unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation without in vitro T-cell depletion","volume":"15","author":"Huang","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.blre.2025.101286_bb0180","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101286_bb0185","first-page":"51","article-title":"Unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation: Peking University Institute of hematology experience","volume":"47","author":"Huang","year":"2010","journal-title":"Semin Hematol"},{"issue":"25","key":"10.1016\/j.blre.2025.101286_bb0190","first-page":"3956","article-title":"Haploidentical vs identical-sibling transplant for hematologic malignancies: impact of transplant-related factors","volume":"125","author":"Luznik","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101286_bb0195","first-page":"S37","article-title":"Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update","volume":"50","author":"Huang","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.blre.2025.101286_bb0200","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.35365","volume":"130","author":"Bazarbachi","year":"2024","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.blre.2025.101286_bb0205","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1080\/14653240802419328","article-title":"Zoledronate facilitates large-scale ex vivo expansion of functional \u03b3\u03b4 T cells from cancer patients for use in adoptive immunotherapy","volume":"10","author":"Kondo","year":"2008","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.blre.2025.101286_bb0210","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.4049\/jimmunol.1103710","article-title":"Human V\u03b39V\u03b42 T cells specifically recognize and kill mycobacterium-infected monocytes","volume":"188","author":"Poccia","year":"2012","journal-title":"J Immunol"},{"issue":"15","key":"10.1016\/j.blre.2025.101286_bb0215","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood-2014-09-599423","article-title":"\u03b3\u03b4 T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-\u03b1\u03b2+\/CD19+ lymphocytes","volume":"125","author":"Airoldi","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2025.101286_bb0220","first-page":"1467","article-title":"Phase I study of zoledronic acid combined with escalated doses of interleukin-2 for early in vivo generation of V\u03b39V\u03b42 T cells after haploidentical stem cell transplant with posttransplant cyclophosphamide","volume":"98","author":"Jullien","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101286_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00699","article-title":"Immune modulation properties of zoledronic acid on TcR\u03b3\u03b4 T-lymphocytes after TcR\u03b1\u03b2\/CD19-depleted haploidentical stem cell transplantation: an analysis on 46 pediatric patients affected by acute leukemia","volume":"11","author":"Merli","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.blre.2025.101286_bb0230","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101286_bb0240","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.20.01719","article-title":"Defining the role of donor lymphocyte infusion in high-risk hematologic malignancies","volume":"39","author":"Schmid","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101286_bb0245","article-title":"The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy","volume":"15","author":"Lurquin","year":"2024","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.blre.2025.101286_bb0255","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.humimm.2022.03.001","article-title":"Review: HLA loss and detection in the setting of relapse from HLA-mismatched hematopoietic cell transplant","volume":"83","author":"Arnold","year":"2022","journal-title":"Hum Immunol"},{"issue":"8","key":"10.1016\/j.blre.2025.101286_bb0265","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/bmt.2011.213","article-title":"Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched\/haploidentical, T-cell-replete hematopoietic HCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis","volume":"47","author":"Wang","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2025.101286_bb0270","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bjh.15544","article-title":"Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high-risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells","volume":"185","author":"Cauchois","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2025.101286_bb0275","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbmt.2013.11.020","article-title":"HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation","volume":"20","author":"Zeidan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2025.101286_bb0280","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/s41409-018-0406-z","article-title":"Chemotherapy plus DLI for relapse after haploidentical HHCT: the biological characteristics of relapse influence clinical outcomes of acute leukemia patients","volume":"54","author":"Sun","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2025.101286_bb0295","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00277-021-04731-5","article-title":"Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Harada","year":"2022","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101286_bb0300","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clml.2019.11.019","article-title":"Donor lymphocyte infusions after allogeneic transplantation: a single-center experience","volume":"20","author":"Kerbage","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.blre.2025.101286_bb0305","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/ejh.14340","article-title":"Inferior overall survival after haploidentical donor lymphocyte infusions in relapsed myeloid neoplasms","volume":"114","author":"Benoit","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101286_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.572918","article-title":"Donor lymphocyte infusions after allogeneic stem cell transplantation in acute leukemia: a survey from the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"10","author":"Patriarca","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101286_bb0315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT","volume":"105","author":"Dholaria","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2025.101286_bb0320","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101286_bb0325","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2002-04-1200","article-title":"G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases","volume":"102","author":"Franzke","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101286_bb0330","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2001-12-0291","article-title":"Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells","volume":"100","author":"Rutella","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2025.101286_bb0335","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood.V95.8.2484","article-title":"Granulocyte colony-stimulating factor mobilizes T helper 2-inducing dendritic cells","volume":"95","author":"Arpinati","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101286_bb0340","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood-2009-11-256495","article-title":"Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma","volume":"116","author":"Hill","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101286_bb0395","first-page":"63","article-title":"Administration of herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions in patients with hematologic malignancies","volume":"97","author":"Heslop","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101286_bb0400","first-page":"91","article-title":"Thymidine kinase gene-transduced donor lymphocyte infusions in patients with hematologic malignancies","volume":"31","author":"Gulati","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2025.101286_bb0405","first-page":"3408","article-title":"Evidence for increased risk of secondary graft-versus-host disease after donor lymphocyte infusion in patients with hematologic malignancies","volume":"104","author":"Storb","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101286_bb0410","first-page":"1401","article-title":"Gene therapy clinical trials for relapsed leukemia with infusions of the suicide-gene transduced donor lymphocytes in Japan","volume":"14","author":"Yamaguchi","year":"2006","journal-title":"Mol Ther"},{"issue":"22","key":"10.1016\/j.blre.2025.101286_bb0415","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood.V128.22.672.672","volume":"128","author":"Mohty","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2025.101286_bb0420","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood.V124.21.548.548","article-title":"GvHD kinetics after haploidentical TK-cells: in-vivo HSV-TK suicide machinery is effective in GvHD control and provides a long-term immune-suppressive treatment-free survival","volume":"124","author":"Lupo-Stanghellini","year":"2014","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2025.101286_bb0425","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/blood-2018-99-119792","article-title":"Administration of rimiducid following haploidentical BPX-501 cells in children with malignant or non-malignant disorders who develop graft-versus-host-disease (GvHD)","volume":"132","author":"Elkeky","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101286_bb0430","author":"American Society of Hematology"},{"key":"10.1016\/j.blre.2025.101286_bb0435","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.blre.2025.101286_bb0440","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12185-017-2379-x","article-title":"NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?","volume":"107","author":"El-Ssen","year":"2017","journal-title":"Int J Hematol"},{"issue":"21","key":"10.1016\/j.blre.2025.101286_bb0445","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVL effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101286_bb0450","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231187932","article-title":"High levels of NK cells in graft are associated with reduced febrile neutropenia after haploidentical peripheral blood stem cell transplantation","volume":"51","author":"Guo","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1016\/j.blre.2025.101286_bb0455","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1266051","article-title":"Persistence of KIRneg NK cells after haploidentical hematopoietic stem cell transplantation protects from human cytomegalovirus infection\/reactivation","volume":"14","author":"Di Vito","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101286_bb0460","first-page":"93","article-title":"Cord blood as a source of natural killer cells","volume":"2","author":"Mehta","year":"2016","journal-title":"Front Med (Lausanne)"},{"issue":"5562","key":"10.1016\/j.blre.2025.101286_bb0465","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.blre.2025.101286_bb0470","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded NK cells in patients with relapsed\/refractory acute myeloid leukemia","volume":"130","author":"Ruggeri","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101286_bb0475","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2025.101286_bb0480","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41375-023-01849-5","article-title":"The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients\u2014a randomized trial","volume":"37","author":"Lee","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2025.101286_bb0485","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2025.101286_bb0490","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101286_bb0495","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101286_bb0500","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using sleeping beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.blre.2025.101286_bb0505","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","article-title":"A good response of refractory mantle cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101286_bb0510","first-page":"771","article-title":"Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML","volume":"9","author":"Hu","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101286_bb0515","first-page":"88","article-title":"Haploidentical CD7 CAR T cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia\/lymphoma","volume":"15","author":"Dai","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101286_bb0520","first-page":"950","article-title":"Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation","volume":"54","author":"Zhang","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2025.101286_bb0525","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41409-020-01140-6","article-title":"Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Hua","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2025.101286_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102377","article-title":"Donor-derived anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HHCT: a phase 1 trial","volume":"67","author":"Luo","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.blre.2025.101286_bb0535","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \u2018off-the-shelf\u2019 allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101286_bb0540","series-title":"Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory\/Relapsed B-Cell NHL","author":"Qian","year":"2024"},{"key":"10.1016\/j.blre.2025.101286_bb0545","series-title":"A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HHCT for B Cell Hematologic Malignancies","author":"Wang","year":"2024"},{"key":"10.1016\/j.blre.2025.101286_bb0550","series-title":"NKG2D CAR-NK & r\/rAML. Identifier NCT05734898","author":"National Library of Medicine (US)","year":"2024"},{"issue":"30","key":"10.1016\/j.blre.2025.101286_bb0555","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101286_bb0560","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jtct.2022.11.013","article-title":"Donor CD7 chimeric antigen receptor T cell bridging to allogeneic hematopoietic stem cell transplantation for T cell hematologic malignancy","volume":"29","author":"Li","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"16","key":"10.1016\/j.blre.2025.101286_bb0565","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HHCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.blre.2025.101286_bb0570","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","article-title":"Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-muenster group","volume":"27","author":"Burkhardt","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.blre.2025.101286_bb0575","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMe2403003","article-title":"CAR as booster to launch allogeneic transplantation in refractory leukemia","volume":"390","author":"Blaise","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101286_bb0580","first-page":"1","article-title":"All-in-one Hangzhou protocol: killing four birds with one stone","author":"Wang","year":"2024","journal-title":"Cell Res"},{"issue":"1 Suppl 1","key":"10.1016\/j.blre.2025.101286_bb0585","first-page":"S29","article-title":"Haploidentical hematopoietic stem cell transplantation: a global overview","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2025.101286_bb0590","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1007\/s00277-022-04971-z","article-title":"Costs of matched-sibling, unrelated, and haploidentical hematopoietic cell transplantation and risk factors for greater financial burden\u2014a Brazilian FACT-accredited single-center analysis","volume":"101","author":"Arcuri","year":"2022","journal-title":"Ann Hematol"},{"issue":"8005","key":"10.1016\/j.blre.2025.101286_bb0595","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/d41586-024-00809-y","article-title":"Cutting-edge CAR-T cancer therapy is now made in India \u2014 at one-tenth the cost","volume":"627","author":"Mallapaty","year":"2024","journal-title":"Nature"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T04:22:15Z","timestamp":1749356535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":117,"alternative-id":["S0268960X25000311"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101286","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Haploidentical transplantation: An optimal platform for graft manipulation and cellular therapies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101286"}}